PRFX Company

PRFX Company: A Comprehensive Overview

1. Company Overview

Founding Date and Background

PRFX, known as PainReform Ltd., was founded in 2007. The company operates within the pharmaceuticals sector, focusing on innovative treatments for pain management. Initially established to develop solutions for chronic pain, PRFX has since broadened its scope to include various pharmaceutical products and services.

Parent Company/Ownership Structure

PRFX is publicly traded on the NASDAQ Capital Market under the ticker symbol PRFX. As a publicly listed company, it is owned by shareholders who hold its stock, with no single entity acting as the parent company.

Headquarters Location

The headquarters of PRFX is located at 65 Yigal Alon St., Tel Aviv, Israel. This strategic location allows the company to leverage Israel's robust biotech and pharmaceutical ecosystem.

Global Business Scope

PRFX operates primarily in the pharmaceutical industry, focusing on the development and commercialization of innovative pain management therapies. Its products are marketed globally, with a significant presence in the United States and Europe.

Main Regulatory Bodies

PRFX is subject to regulations from various health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory bodies ensure that the company's products meet safety and efficacy standards before they can be marketed to consumers.

2. Company History and Development

Key Milestones

• 2007: PRFX was founded, focusing on pain management solutions.
• 2020: The company went public on NASDAQ, enhancing its visibility and access to capital.
• 2021: PRFX successfully completed clinical trials for its lead product, demonstrating significant efficacy in pain management.

Business Expansion Journey

Over the years, PRFX has expanded its product line and market reach. The company has engaged in strategic partnerships with other pharmaceutical firms to enhance its research capabilities and distribution networks, allowing for a more extensive global footprint.

Customer Base Growth

PRFX has experienced steady growth in its customer base, particularly among healthcare providers and patients seeking effective pain management solutions. The company has established relationships with hospitals and clinics, facilitating the adoption of its products.

Platform Development History

The company has invested significantly in research and development, leading to the creation of innovative formulations and delivery methods for its pain management therapies. This commitment to R&D has positioned PRFX as a leader in the pain management market.

Important Awards or Recognitions Received

PRFX has received several awards for its innovative approaches to pain management, including recognition from industry bodies for its contributions to improving patient outcomes in chronic pain management.

3. Trading Services Offered

Forex Trading Options

While PRFX primarily operates in the pharmaceutical sector, it does not directly engage in forex trading. However, its public trading on NASDAQ allows investors to buy and sell shares in the company, indirectly participating in the financial markets.

Stock Trading Options

Investors can trade PRFX shares on the NASDAQ Capital Market, providing access to the company's equity for those interested in investing in its growth and development.

CFD Trading Products

PRFX does not offer Contracts for Difference (CFDs) directly. However, investors can trade PRFX shares as part of their broader investment strategies through various brokerage platforms that provide CFD options.

Other Financial Instruments

PRFX focuses on pharmaceutical products and does not engage in trading cryptocurrencies, commodities, or other financial instruments. Its business model is centered around the development and commercialization of pain management therapies.

Special Services or Unique Advantages

PRFX's unique advantage lies in its innovative approach to pain management, backed by a strong R&D pipeline. The company's commitment to improving patient outcomes and its focus on chronic pain solutions differentiate it from competitors in the pharmaceutical industry.

4. Regulatory and Legal Background

Detailed Regulatory Information

PRFX operates under the regulations of several key bodies:

• U.S. Food and Drug Administration (FDA): Oversees the approval and regulation of pharmaceutical products in the United States.
• European Medicines Agency (EMA): Regulates pharmaceutical products within the European Union.
• Other regional health authorities as required for international markets.

Legal Entity Structure by Region

PRFX operates as a single legal entity registered in Israel. Its public listing on NASDAQ allows it to operate under U.S. securities laws while complying with Israeli corporate regulations.

Client Fund Protection Measures

As a publicly traded company, PRFX is subject to stringent financial regulations that require it to maintain transparency in its financial reporting and operations. Client funds are protected through adherence to regulatory standards, although the nature of its business does not involve direct client fund management typical of financial trading firms.

Countries/Regions Served

PRFX markets its products primarily in the United States and Europe, with plans for further expansion into other international markets as regulatory approvals are obtained.

Compliance History

PRFX has maintained a strong compliance record, adhering to the regulations set forth by the FDA and EMA. The company has not faced any significant legal challenges or sanctions that would impact its operations or reputation.

5. Competitive Landscape

3-5 Main Competitors

1. AbbVie Inc.: A global biopharmaceutical company specializing in pain management and other therapeutic areas.
2. Pfizer Inc.: A leading pharmaceutical company with a diverse portfolio, including pain management products.
3. Johnson & Johnson: A multinational corporation with a significant presence in the pharmaceutical sector, including pain relief medications.

Positioning in the Industry

PRFX positions itself as a specialized provider of innovative pain management therapies, focusing on chronic pain solutions. Its commitment to R&D and patient outcomes sets it apart from larger pharmaceutical companies that may have broader but less specialized offerings.

Market Differentiation Factors

PRFX differentiates itself through its focused approach to pain management, innovative product development, and strong clinical evidence supporting its therapies. The company's agility as a smaller entity allows it to respond quickly to market needs and patient demands, providing a competitive edge in the pharmaceutical landscape.

For more information on PRFX and its offerings, please visit their official website.

Back to top

This article provides a detailed overview of PRFX, its operations, and its position in the pharmaceutical industry, highlighting its commitment to innovation and patient care.